Board of Directors

Michael co-founded ImStem and has served as Chairman and head of the Board of Directors since our founding. At ImStem, Michael has overseen the company operations and is responsible for making major decisions. He worked to create a research team with global talents that led to the development of IMS001 as well as its clearance for clinical trial by the FDA in 2020. IMS001 is believed to be the first human embryonic stem cell derived-mesenchymal stem cell (hES-MSC) based allogeneic cell therapy product accepted for clinical trial by the FDA. Michael has brought his experience and unique vision in clinical medicine and product commercialization into establishing our multi-center research platform that attracted collaborations from numerous universities and clinical centers, with a goal of accelerating the translational process of our product pipelines from research to patients.

 

Michael’s involvement with cutting edge medical therapies started when he studied for his medical degree at the Southern Medical University. After graduation, he worked as a physician in Guangdong Provincial People's Hospital. Years of clinical experience has helped build his drive to explore better and more effective therapies for patients in need of help. Michael believes that the best way to achieve more advanced therapies is through investing in innovative scientific research and attracting best talents across science and business. As a founder and angel investor, Michael is a passionate proponent for research and clinical translation of stem cell therapies. Michael is a member of the committee of the 6th China Medicinal Biotech Association and was certified as the Pioneer Fighter of Covid19 Outbreak.

Dr. Wang is the co-founder and Chief Technology Officer (CTO) of ImStem. Dr. Wang is responsible for providing technology strategy, implementing major technical programs and building up company's pipeline. He is in charge of technology development, quality control, and manufacturing development in compliance with all required regulations. 

 

Dr. Wang has over 15 years of extensive experience in immunology and stem cell biology. He is a key inventor of the proprietary two-step method in differentiating human embryonic stem cells into mesenchymal stem cells. T-MSCs derived using this method are consistent, well-defined, of preferred biological properties and can also be expanded almost indefinitely, making T-MSCs the ideal off-the-shelf, allogenic stem cell therapy product to treat a wide range of autoimmune and neurodegenerative diseases.

 

He received his M.D. from Peking University after being admitted into the highly competitive seven-year program in Clinical Medicine. He obtained his PhD degree in Immunology from University of Texas-Houston/MD Anderson Cancer Center. Dr. Wang worked as a postdoctoral fellow at Yale School of Medicine and University of Connecticut’s Stem Cell Institute before he founded ImStem Biotechnology, Inc. and has been awarded multiple stem cell research grants from the State of Connecticut totalling more than 1.3 million dollars.

Mr. Wang has over 20 years of experience in top executive positions of various listed companies. Since 1994, he has served as the CEO of Everbright Investment Consulting Company, CEO of China Everbright Holdings Co., Ltd. (a company listed on the Hong Kong Stock Exchange), Directors of several Hong Kong listed companies such as International Bank of Asia and National Mutual of Asia. Mr. Wang also undertook leadership roles in multiple international companies, including Director of Citicorp Everbright China Fund (listed in Ireland); Director of China Everbright Asia Pacific Co., Ltd. (listed in Singapore); and President of Deppon Securities. In the last 10 years, Mr. Wang held the position as Chairman of Beijing Institute of Technology, Zhuhai, where he successfully runs the university by transforming it from 165 million dollars in debt and 7,126 dollars in cash to debt free with 264 million dollars cash on account. 

 

Mr. Wang graduated with a master's degree in law and obtained his Ph.D. in Economics from Peking University. He then went on to study in the U.S. and got a master's degree in finance from Bowling Green State University and then worked as a postdoc research fellow at Harvard University with a full scholarship.